To assess predictors of treatment response in neovascular age-related macular degeneration (AMD) in an attempt to develop a patient-centric treatment algorithm. We conducted a systematic search using PubMed, EMBASE and Web of Science for prognostic indicators/predictive factors with the key words: 'age related macular degeneration',
Introduction
Age-related macular degeneration (AMD) is the major cause of visual loss in individuals 50 years or older in developed countries, affecting nearly 10% of those >65 years of age and affecting >25% of those >75 years of age (Smith et al. 2001) . Anti-vascular endothelial growth factor (anti-VEGF) therapy is currently the treatment of choice for cases with neovascular AMD. The main purpose of this treatment is to suppress the activity of the CNV and to maintain this suppression with as little recurrences as possible. Several protocols and treatment regimens have been introduced aiming at achieving maintained visual gains over extended periods of time. Strategies include monthly or bimonthly treatments, as needed (pro re nata), TAE or observe and plan (OAP) (Martin et al. 2011; Mantel et al. 2014; Berg et al. 2015) . Whilst there is some debate as to the best treatment protocol, the choice of regimen is usually independent of patient demographics or baseline clinical features.
Prognostic indicators are predictive factors that provide an indication as to the expected patient response to therapy. Response usually refers to improvements in VA, anatomy and indirectly injection frequency. Most of the studies that looked at predictive indicators were retrospective in nature and had a relatively small number of patients (Kolb et al. 2012; Kwon et al. 2014; Suzuki et al. 2014; Margaron et al. 2015; Oishi et al. 2015; Kikushima et al. 2016; Tsilimbaris et al. 2016) . One of the drawbacks of retrospective studies is the lack of a strict adherence to a specific injection protocol, irregular patient follow-ups and lack of uniformity with regard to the treatment drug or regimen. In addition, many of these studies failed to look at predictive factors for less injection frequency. Most of the data from prospective studies are usually in the form of a post hoc analysis of previous phase 3 trials.
There have been two previous reviews looking at prognostic factors in patients treated with anti-VEGF therapy in wet AMD (Finger et al. 2014; Tsilimbaris et al. 2016) . However, these reviews did not intend to specifically look at morphological predictors of injection frequency, and instead focused on final visual outcomes. The aim of this review was to analyse studies that have looked at morphological prognostic indicators and injection frequency to identify specific patient subgroups that could benefit from less intensive therapy. A secondary objective was to propose a modified algorithm incorporating predictive factors in an attempt generate a more patient-centric approach to therapy.
Materials and Methods
We conducted a systematic search using PubMed, EMBASE and Web of Science for prognostic indicators/predictive factors with the key words: 'age related macular degeneration', 'neovascular AMD', 'CNV', 'anti-VEGF', 'aflibercept', 'ranibizumab', 'bevacizumab', 'randomized clinical trials', 'post-hoc', 'prognostic', 'predictive', 'response' 'injection frequency, 'TAE, 'PRN', 'bimonthly' and 'quarterly'.
We only included studies that had an adequate period of follow-up (>1 year), a single predefined treatment regimen and a predetermined reinjection criteria, an adequate number of patients, had morphological (OCT) criteria that predicted final visual outcomes and injection frequency, did not switch from one drug to the other and were published in English. We did not include studies that did not look at anatomical end-points and studies that relied on an exclusively monthly or bimonthly treatment regimen. We stratified our findings into two groups: prognostic indicators from prospective studies and retrospective studies. We included all studies until August 2016. Using this search strategy, we identified seven prospective studies that met our criteria and 19 retrospective studies.
Results

Prognostic Indicators from prospective studies
Prospective studies that were identified were mainly phase 3 randomized clinical trials, most of whom had conducted post hoc analysis looking at prognostic indicators. We excluded from our analysis ANCHOR/MAR-INA because they relied on monthly therapy and included VIEW1/VIEW2 because of the PRN extension phase of the study (Boyer et al. 2007) . Furthermore, we excluded studies that did not perform post hoc analysis of prognostic indicators such as LUCAS (Berg et al. 2015) , SAILOR and SUSTAIN. As our focus was response to anti-VEGF therapy, in studies that had arms with alternative treatment modalities such as photodynamic therapy (PDT) or combined PDT/anti-VEGF, we only focused on patients receiving anti-VEGF therapy alone. A summary of the main prognostic indicators is shown in Table 1 .
Subretinal fluid
Subretinal fluid (SRF) was identified as a strong prognostic factor in several studies. A post hoc analysis of the EXCITE study identified SRF as a predictor for greater best-corrected visual acuity (BCVA) gains at 12 months of treatment (p = 0.05) (Waldstein et al. 2016a,b) . The presence of baseline SRF was associated with comparable visual gains at 12 months in patients receiving monthly and quarterly injections of ranibizumab (difference of +0.9 letters between both groups). However, in patients without baseline SRF, the difference between monthly and quarterly regimens was +12.3 in favour of monthly injections. When looking at the combined effect of SRF and the vitreomacular interface, only patients having both SRF and PVD (42 in the monthly group versus 80 in the quarterly group) showed similar BCVA gains at 12 months with a mean letter gain difference of 2.6 letters in favour of the quarterly group. Despite similar baseline visual acuities, there were significant differences between visual outcomes in patients receiving monthly and quarterly injections in all other patients groups (VMA+/SRFÀ, VMAÀ/SRF+, VMAÀ/SRFÀ) and in particular the group with VMA and no SRF where the difference was close to 16 letters in favour of the monthly dosing. This indicates that patients with both SRF and a PVD could benefit from less intensive treatment regimens.
In the subgroup analysis of the HARBOR which used a PRN treatment regimen, patients with SRF at baseline had a greater likelihood of achieving a VA of 20/40 or better and had a greater chance of gaining >15 letters especially if the CNV leakage area was <4.51 DA. However, the same post hoc analysis found that patients with greater SRF thickness at baseline required 1.6 injections more than patients with a SRF <118 lm at baseline indicating that the volume of SRF is an independent variable that should be considered (Busbee et al. 2013) . The effect of SRF on final VA was also confirmed by the post hoc of the MONT BLANC study which found that in patients treated with as needed ranibizumab, SRF did not have a negative predictive value alone and only affected final visual gains when combined with IRC (Ritter et al. 2014 ). In addition, contrary to the findings of the EXCITE study, SRF was found to be associated with an increase in retreatment frequency (+0.8 injections in the ranibizumab group). However, the study did not look at the combined effect of SRF and PVD and only looked at SRF as an independent variable. Finally, in the VIEW1/VIEW 2 studies, patients with SRF achieved 2.11 more letter at 12 months compared to patients with IRC or PED at baseline regardless of the drug used (ranibizumab or aflibercept) (Waldstein et al. 2016a,b) .
In summary, patients with SRF appear to have higher visual gains and reduced injection frequency provided that they are associated with a PVD.
Pigment epithelial detachment
In the EXCITE study, PED and central retinal thickness (CRT) did not significantly predict BCVA gains at 12 months (Waldstein et al. 2016a,b) . Similarly, in the MONT BLANC study, PED did not have a negative predictive value when it came to visual gains at 12 months of the study (Ritter et al. 2014) . Pigment epithelial detachment (PED) only affected final visual gains when combined with IRC. However, PED was associated with an increase in retreatment frequency. A post hoc of the result of VIEW 1/ VIEW 2 looked at the association between various morphological features and functional outcomes (Waldstein et al. 2016a,b) . The study found that regardless of the drug used, the presence of IRC and PED at baseline was associated less BCVA change from baseline at week 52 (2.11 less letters for IRC and 1.88 less letters for PED) compared to SRF which was associated with 2.11 letters more BCVA change from baseline at week 52. When patients were shifted to a PRN dosing regimen in the 96-week extension phase of the study, all patient groups showed a 1-2 letter drop in visual gains (Schmidt-Erfurth et al. 2014 ). This was attributed mainly to the recurrence of fluid activity in patients with baseline PED in both the ranibizumab and aflibercept groups. Once patients were shifted to a variable-dosing regimen eyes of other morphological groups (IRC and SRF) remained stable, whereas those with PED (with or without baseline IRC) showed a steady decline in VA. The drop in vision appears to correlate more with recurrent fluid activity as opposed to residual fluid activity (particularly SRF). The authors concluded that patients with baseline PED were more likely to develop recurrences and activity when shifted from a fixed dosing regimen to a more flexible dosing regimen (SchmidtErfurth et al. 2015; Schmidt-Erfurth & Waldstein 2016 ). They also concluded that patients with baseline PED should be monitored very closely and that the inferiority of PRN in several trials compared to monthly can be attributed mainly to this subgroup of patients (Lalwani et al. 2009; Martin et al. 2011 Martin et al. , 2012 . Therefore, it would appear that PED does not affect final visual outcomes but is associated with an increased treatment frequency.
Intraretinal cysts
In the EXCITE study, in contrast to PVD and SRF, IRC at baseline is a bad prognostic factor in terms of BCVA gain (+3.6 letters when IRC is absent versus present, p = 0.05). However, IRC did not have any significant impact on differences in visual outcomes as a function of treatment frequency, with eyes in both the quarterly and the monthly group achieving similar visual gains (Waldstein et al. 2016a,b) . In the MONT BLANC study ranibizumab PRN arm, SRF and PED did not have a negative predictive value alone and only affected final visual gains when combined with IRC (Ritter et al. 2014) . Patients with IRC also had the worst baseline BCVA. However, with regard to the number of injections, IRC did not have an impact on the total number of injections whereas both SRF and PED were both associated with an increase in retreatment frequency. A post hoc analysis of the VIEW1/VIEW2 studies also found that the presence of baseline IRC was associated with 2.11 less letters gained at 12 months compared to eyes without IRC (Waldstein et al. 2016a,b) . Together, these data indicate that IRC is a poor visual prognostic indicator but did not affect the frequency of injections.
The vitreomacular interface
The effect of the vitreomacular interface was studied in several post hoc analysis of large RCT. A post hoc analysis of the EXCITE study looked at visual gains in cases with PVD and no PVD at baseline as well as cases who had developed a release of the vitreomacular interface during the course of the study (RELEASE) (Mayr-Sponer et al. 2013 ). In the PVD group, the mean letter gains after 12 months were +4.7 letters in the quarterly treatment group and +4.9 letters in the monthly group. Quarterly dosing was not inferior to monthly dosing in cases with PVD. In the VMA group, the mean VA gains were À0.2 letters in the quarterly group compared to +7.5 letters in the monthly treatment group (p = 0.043). Patients with RELEASE gained more letters than patients with VMA, and this difference was observable even during the loading phase. There were some unexplained findings in the study with patients in the RELEASE group achieving higher visual gains than the PVD group (+12.7 letters in the monthly group versus 3.2 letters in the quarterly group compared to 4.7 in the PVD group). Whilst it could be explained that the effect of RELEASE (+3.2 letters) allowed those patients to achieve similar visual gains as the PVD group (+4.7 letters versus À0.3 letters in the VMA quarterly group), it does not explain why the monthly gains of RELEASE (+12.7) and VMA (+7.5) groups were higher than the monthly gains in the PVD group (+4.9 letters). It is also surprising that the PVD group showed poor gains even in the loading phase. Perhaps the age difference (as postulated by the authors; PVD patients were generally older) or the association between certain CNV subtypes or morphologies with VMA or RELEASE could explain this discrepancy.
A post hoc analysis was published that looked particularly at the vitreomacular interface in the MONT BLANC study (Ritter et al. 2014 ). In the ranibizumab monotherapy group, mean BCVA gains from baseline to the end of the loading phase at month 3 were +8.4 letters for PVD, +4.7 letters for the release group and +6.6 letters for VMA. During the PRN phase from month 3 to month 12, the PVD group lost 5 letters compared to À0.4 letters in the RELEASE group and +0.6 letters in the VMA group, but these differences were not statistically significant. The authors therefore concluded that 'Despite the less specific response patterns in patients with VMA and release of VMA-which could also be attributed to sample size limitationsour results imply that this defined patient subgroup should preferentially not be switched to a discontinuous treatment regimen in clinical practice'.
With regard to the CATT study, a post hoc analysis looked at the association between the vitreomacular interface, treatment outcomes as well as treatment frequency (Cuilla et al. 2015) . The vitreomacular interface did not affect visual outcomes at 1 year or 2 year of the study but the percentage of patients who developed geographic atrophy was lower in patients with VMA or VMT at baseline (p = 0.02 at year 1 and p = 0.005 at year 2). The presence of VMA/VMT did not affect the efficacy of anti-VEGF therapy as there was no difference in the percentage of patients within each group having intraretinal fluid at year 1. However, the presence of baseline VMA/VMT was associated with an increased, albeit not statistically significant, number of injections at year 1 (mean 7.89 versus 7.19, p = 0.08) and year 2 of follow-up (14.8 versus 13.1, p = 0.052).
Therefore, patients with VMA/VMT appear to require more frequent injections. The number of injections is reduced in patients with PVD especially if combined with SRF.
Early response to treatment
Early response to anti-VEGF was correlated with greater final VA gains in several studies. In the CATT study, the most predictive factor for year 1 and year 2 visual outcomes was the VA response of the patient at 12 weeks . This was more predictive than week 4 visual response and baseline VA. To evaluate whether baseline characteristics, early VA response or both predict vision outcomes at years 1 and 2, the study calculated R 2 from linear regression models using various predictors . The study included in their calculation the baseline predictors that significantly predicted visual outcomes and found that the predictive power of baseline criteria was minimal compared to VA response at week 4 and week 12. Week 12 visual response was the most predictive factor with an R 2 of 0.47 for year 1 and 0.30 for year 2 compared to 0.09 and 0.13 for the year 1 and year 2 predictive powers of baseline characteristics (p < 0.001 for comparison between week 12 and baseline characteristics). This would seem to indicate that most baseline characteristics could only minimally predict final visual outcomes and that the most significant predictive factor for a patient's final outcomes is his initial response to anti-VEGF therapy. This is in line with previous results from the PRONTO study (Lalwani et al. 2009 ), which showed that OCT changes at 1 month significantly correlated with the VA changes at month 2 (Pearson, r = 0.57, p < 0.001), month 3 (Pearson, r = 0.51 and p = 0.001), month 12 (Pearson, r = 0.37 and p = 019) and month 24 (Pearson, r = 0.41 and p = 0.011).
In the PIER study, qualitative OCT showed that approximately 60% of eyes had no fluid activity after three injections of ranibizumab . The authors concluded that the majority of 'early responders' can be determined after the first three injections. Approximately 30% of patients who were switched to quarterly dosing showed recurrent activity at month 5. This can be interpreted that whilst some patients required more intensive therapy to prevent recurrences, there was a subgroup of patients for whom quarterly dosing was adequate. The analysis also demonstrated that the longer the anatomical improvements were maintained on OCT and FFA, the more likely the BCVA gains after the first three loading of ranibizumab were maintained at 12 months. Eyes with inactive FFA lesions at month 3 gained 10.2 letters at month 12 whereas those with active lesions had lost 1.8 letters during the same time period (p = 0.0045). In contrast, the BCVA outcomes of those patients with dry OCTs at months 5 and 8 were not statistically different from those with fluid at the same time interval (p = 0.33 and 0.09) at 12 months. However, their BCVA outcomes were significantly different at month 24 (p = 0.045 and 0.0096, respectively). It is worth noting that the percentage of eyes with inactive FFA lesions (10%) and the number of eyes that were dry on OCT (60%) at 3 months. This discrepancy might be explained by the fact that only two scans were available for grading on OCT rather than all six radial line scans, meaning that the possibility of missing fluid activity was probably high. In addition, the authors suggested that leakage in FFA persisted even after dryness on OCT and that this might be explained by an effective RPE mechanism that dries the retina despite leakage through the CNV.
In the VIEW1/VIEW2 studies, the effect of fluid status at week 12 on final VA outcomes at week 52 was studied (Moshfeghi et al. 2016) . At week 12, 35% of all eyes included in the study had retinal fluid present and 65% of eyes had no signs of fluid activity. The study also found that patients treated with aflibercept were more likely to be fluid free at week 12 compared to patients treated with ranibizumab (28% and 19% lower chance in the 2q4 and 2q8 groups). The study also found that the mean change in vision from baseline to week 52 did not differ significantly in any of the treatment groups regardless whether fluid activity was detected or not at week 12 (p = 0.1013). In the post hoc analysis of patients extended to 96 weeks, those with persistent IRC at week 12 had a higher recurrence rate with half of patients showing 5 or more recurrences indicating that these patients will probably require more intensive therapy (Schmidt-Erfurth et al. 2015) .
In summary, SRF activity at week 12 was not predictive of final visual outcomes whereas IRC at week 12 predicted a poor prognosis with a possibility of repeated recurrences. In addition, early visual response to therapy was a strong predictor for final visual gains.
Baseline visual acuity
In the PRONTO study, baseline VA did not affect the number of reinjections (p = 0.39, r = 0.14) (Lalwani et al. 2009 ). In the post hoc analysis of the HARBOR study, significant baseline predictors of better VA outcomes at month 12 included lower baseline BCVA (<44 letters or <20/125 on the Snellen chart) (Busbee et al. 2013) . These findings are similar to the results of the analysis of the CATT study, which revealed that baseline predictors for less VA at year 1 and year 2 included older age, baseline VA of 20/40 or better in the study eye . In the VIEW 1/VIEW2 studies, it was found that for each letter increase at baseline, there was an associated 0.25 letters decrease in BCVA gain at week 52 for patients with the same fluid morphology (Schmidt-Erfurth et al. 2015; Waldstein et al. 2016a,b) .
Lesion type and CNV size
Smaller CNV size (<5.24 DA) at baseline was not predictive of final visual outcomes at month 12 in the HAR-BOR study (Busbee et al. 2013 ). In the PIER study, eyes with lesions >4 DA (disc areas) at baseline lost more letters (À4.3) compared to eyes with <4 DA at baseline (À0.10), (p = 0.13) . Similar findings were also demonstrated in the CATT 1 and 2 year post hoc analysis .
Type of CNV and demographic factors such as race or sex did not predict final visual outcomes or treatment frequency in the HARBOR study (Busbee et al. 2013 ). In the Pronto study, baseline angiographic lesion types did not affect the mean number of injections (p = 0.67) (Lalwani et al. 2009 ). Similar results were seen in the PIER study which showed that there was no significant difference in the visual gains between the different subtypes of CNV (occult, predominantly classic and minimally classic), p = 0.90 ). In the CATT study, baseline predictors for less VA at year 1 and year 2 included the absence of RAP and the presence of RPE elevations on OCT . In addition, there were two more factors that only predicted visual outcomes at 2 years and they included geographic atrophy at baseline and a thicker (>425 lm) or thinner (<325 lm) total foveal thickness.
Prognostic indicators from Retrospective trials
There were 18 retrospective studies that met the initial inclusion criteria (Table 2 ). In 12 studies, patients were treated with ranibizumab, three studies where they were treated with bevacizumab and one study where patients were treated with aflibercept. All studies used a pro re nata (or as needed) treatment regimen except for one study which used a treat-andextend regimen.
There were five studies that identified higher baseline VA as a predictor for better final VA (Kang & Roh 2009; Shona et al. 2011; Tran et al. 2011; Granstam et al. 2016 ). Only two studies showed a correlation between final visual outcomes and CNV size, with patients having a large baseline CNV achieving less visual gains (Kang & Roh 2009; Yamashiro et al. 2012 ). Four studies identified older age as a risk factor for poor visual outcomes and response (Yamashiro et al. 2012; Suzuki et al. 2014; Kuroda et al. 2015; Granstam et al. 2016) . With regard to the vitreomacular interface, it was found that the presence of VMA was associated with relatively poor visual outcomes, with patients having a complete PVD showing higher visual gains (Nomura et al. 2014; Uney et al. 2014) . One study found that type 1 CNV was associated with better long-term vision compared to types 2 and 3 (Chae et al. 2015) .
Several studies looked at factors that affected injection frequency and treatment intervals. One study looking at angiographic response to therapy found that the pattern of angiographic Group with PVD had the longest intervals between treatment and least number of injections (versus VMA and ERM) response can be predictive of injection frequency with patients showing regression of the lesion having less total injections compared to patients having a residual lesion with or without leakage (Tran et al. 2011) . One study identified pseudophakia as a risk factor for higher recurrence rates and increased frequency of treatment (Wang et al. 2013) . The same study found that males had a 2.19 greater risk of recurrence with higher injection frequency, a finding that was confirmed by Kuroda et al. (2015) who found that males required more retreatments during the first year. Three studies identified the presence of a PVD was associated with less injection frequency (Uney et al. 2014; Houston et al. 2015; Karaca et al. 2015) . In addition, one study found that the presence of an ERM correlated with higher injection frequency (Karaca et al. 2015) . There were several studies that looked at optical coherence tomography angiographic (OCTA) patterns of AMD in active and inactive cases (Coscas et al. 2015; Sulzbacher et al. 2017) . A recent study was unable to show morphological differences between responders and nonresponders using various qualitative and quantitative OCTA parameters (Roberts et al. 2016 ).
Modified treatment algorithm using morphological predictors
There have been many treatment protocols suggested for the treatment of wet AMD: monthly, bimonthly, quarterly, PRN and TAE. Because of high costs, the feasibility of maintaining a monthly or bimonthly dosing regimen is difficult. Data from CATT 2 year as well as the VIEW1/VIEW2 96-week extension have illustrated that patients being maintained on monthly/bimonthly dosing regimen who were switched to a more flexible dosing regimen lost VA gains achieved with fixed dosing (Martin et al. 2012; Schmidt-Erfurth et al. 2014) . Approximately 23% of patients experience a loss of 5 EDTRS letters immediately after being switched to a PRN dosing regimen in the VIEW/VIEW2 study (Richard et al. 2015) . In the case of CATT, patients who were switched from monthly to PRN in the second year showed a decrease in visual gains achieving levels comparable to those who were on PRN therapy from the start. This is a clear indication that for a subgroup of patients, the advantage monthly therapy has over PRN is only maintained as long as patients are continued on monthly therapy. Furthermore, as illustrated by long-term follow-up studies including the CATT 5-year and the SEVEN-UP study, unless patients are followed meticulously and receive adequate treatment, they will continue to lose initial visual gains on the long run (Brijesh & Shorya 2016; Maguire et al. 2016) .
The most commonly used treatment regimens in AMD are PRN and TAE based on an ASRS survey. A recent systematic review comparing between PRN and TAE dosing regimens found that patients being treated with TAE achieved higher visual gains at 1 year (8.09 letters) compared to patients treated using an as needed dosing regimen (5.60 letters) (Chin-Yee et al. 2016) . In addition, patients who were treated using a PRN regimen showed further improvement in BCVA after being switched to TAE, highlighting the greater efficacy of TAE compared to PRN (Kvannli & Krohn 2017) .
Early studies looking at TAE found that approximately 45.7% of eyes treated with ranibizumab and 52.7% of eyes treated with bevacizumab did not develop a single recurrence, reaching the 3-month extension period without fluid activity (Gupta et al. 2010; Shienbaum et al. 2012 ). Very few patients had persistent exudation that did not resolve on anti-VEGF treatment (7% in both groups). The VIEW studies identified a subgroup of patients (approximately 43% in the 0.5 mg ranibizumab groups, 54% in the 2q4 aflibercept group, 44% in the 0.5q4 aflibercept group and 48% in the 2q8 aflibercept group) who received scheduled to mandated 3 monthly injections if they did not develop fluid activity in the PRN 96-week extension of the study (Richard et al. 2015) . This is similar to data from EXCITE that showed that approximately 40% of patients did equally well on quarterly dosing as they would have on monthly therapy (Eldem et al. 2009; SchmidtErfurth et al. 2011) . Data from the LUCAS study have illustrated that the majority of patients will require either monthly therapy (46.7% for bevacizumab and 32.9% for ranibizumab) or will reach an extension of 10-12 weeks (32.3% for bevacizumab and 47.7% for ranibizumab). In addition, very few patients required fixed injections at 6 or 8 weeks (Berg et al. 2015) . The data would seem to indicate that for at least 40-45% of patients with wet AMD, 10-to 12-week extensions is a possibility (Table 3) .
Using morphological predictors for reduced injection frequency, we can modify the existing TAE regimen for selected patients. A recent modification to the TAE regimen is a new protocol called OAP (Mantel et al. 2014) . Details of the regimen are highlight in the paper by Mantel et al. (2014) and revealed good visual outcomes at 1 and 2 years of therapy (Gianniou et al. 2015) . In brief, after achieving dryness, patients are followed up every month using OCT and VA until fluid recurrence or reaching the 3-month extension. If fluid recurrence occurs, the fixed treatment interval is set at 'exudation interval minus 2 weeks'. For patients who are predicted to require less intense therapy (PVD and SRF), the extended monthly follow-ups without the need for mandatory injections would seem to be a more suitable alternative. However, for other patients who do not have these morphological criteria biweekly 'TAE' would be the protocol of choice. Furthermore, for patients with PED, data from the post hoc analysis of VIEW1/VIEW2 have shown that the visual loss in the variable-dosing extension of the study (week 48-96) was mainly driven by reactivation of PED with subsequent development of IRC (Schmidt-Erfurth et al. 2015) . The authors suggested that for patients with PED fixed dosing regimens (monthly/bimonthly) or cautious TAE with increasing intervals of 2 weeks would be the most adequate treatment protocol to maintain visual gains (Schmidt-Erfurth et al. 2015; Schmidt-Erfurth & Waldstein 2016) .
Finally, to commence the extension of injection intervals, patients must first achieve dryness or absent fluid activity. A study by Gillies et al. (2015) that looked at 1096 eyes found that 1-3 injections were sufficient to inactivate 61% of eyes with a mean of 3.7 injections. In the VIEW1/VIEW2 studies, 65% of patients had absent fluid at 12 weeks of therapy (Moshfeghi et al. 2016) . Therefore, approximately 30-35% of eyes at 3 months would still have residual fluid. The post hoc analysis from CATT showed that patients eligible for switching at 3 and 6 months achieved comparable results when maintained on the same treatment drug compared to patients who were switched to aflibercept . In addition, a recent post hoc analysis by Jaffe et al. (2016) showed that patients with residual fluid at 3 months achieved significant visual gains when maintained on the same dosing regimen: monthly ranibizumab, monthly aflibercept or bimonthly aflibercept. Whilst the debate about switching is outside the scope of this paper, it would seem logical to continue the same anti-VEGF at least for the first 9-12 months of therapy before attempting to switch the patient to an alternative drug. A summary of the modified treatment algorithm is shown in Fig. 1 .
Summary
There are several morphological and demographic prognostic indicators that can predict response to therapy in wet AMD. Smaller CNV size, SRF, RAP and response to therapy at 12 weeks (visual, angiographic or OCT) can all predict good visual outcomes in patients receiving anti-VEGF therapy. Patients with larger CNV, older age, PED, IRC and VMA achieved less visual gains. Patients having VMA/ VMT required more intensive treatment with increased treatment frequency.
A regimen that involves less intensive therapy and extended follow-up intervals (4 weekly) can be suggested for patients who show adequate visual response and have both SRF and PVD at baseline. In addition, patients with poor prognostic indicators such as IRC, VMA, large CNV size, older age and poor response at 12 weeks should be extended very cautiously (2 weekly intervals) with the possibility of fixed monthly/bimonthly treatments if they fail to achieve dryness. Patients with PED at baseline should receive fixed monthly/bimonthly injections of anti-VEGF therapy or can be extended very cautiously (2 weekly) using a treat-and-extend protocol. Finally, switching as an option can be reserved for cases that fail to respond to primary therapy after 9-12 months of therapy. 
